Over 9.8% of children in the US have atopic dermatitis (AD), which is associated with significant disability and poor quality of life. While progress has occurred in the development of advanced therapies capable of improving response in poorly controlled AD, challenges still exist, including lack of prescriber confidence due to unfamiliarity of mechanisms of action of new and emerging agents.

This activity, with expert faculty Dr. Anthony Mancini, will explore AD pathophysiology, review newly approved therapies and their place in treatment, and will present the latest on emerging agents, along with a patient ambassador sharing their experience with AD.

The injection of botulinum toxin type A products can diminish unwanted facial wrinkles and improve appearance. Do you fully understand how to use these products? Tune in as Dr. Jason Bloom and Dr. Carolyn Jacob take us through the pharmacologic similarities, differences, and duration of effect for the 4 FDA-approved neuromodulators and demonstrate specific injection techniques for the masseter, platysma bands, “bunny lines,” and the glabellar complex.

Iron deficiency, independent of anemia status, is common in heart failure and is associated with increased risk for heart failure hospitalization and cardiovascular mortality, reduced functional status, and poor exercise performance. This impact may be magnified in patients with ischemic etiology. Join Dr. Marco Metra and Dr. Piotr Ponikowski as they discuss the clinical relevance of ischemic etiology in the management and outcomes of patients with heart failure and iron deficiency.

The purpose of this program is to create awareness about the emergence of NRG1 fusions as a clinically actionable target, leading to new opportunities to increase patient referral due to a greater understanding of this ERBB[/HER]-targeted agents in NRG1 fusion-positive cancers. Researchers still do not fully understand many aspects of this targeting, raising the importance of foundational education to apprise clinicians of the latest mechanistic and preclinical data, so they become more comfortable to ask and detect and then refer.

The purpose of this program is to create awareness about the emergence of NRG1 fusions as a clinically actionable target, leading to new opportunities to increase patient referral due to a greater understanding of this ERBB[/HER]-targeted agents in NRG1 fusion-positive cancers. Researchers still do not fully understand many aspects of this targeting, raising the importance of foundational education to apprise clinicians of the latest mechanistic and preclinical data, so they become more comfortable to ask and detect and then refer.

The purpose of this program is to create awareness about the emergence of NRG1 fusions as a clinically actionable target, leading to new opportunities to increase patient referral due to a greater understanding of this ERBB[/HER]-targeted agents in NRG1 fusion-positive cancers. Researchers still do not fully understand many aspects of this targeting, raising the importance of foundational education to apprise clinicians of the latest mechanistic and preclinical data, so they become more comfortable to ask and detect and then refer.

The purpose of this program is to create awareness about the emergence of NRG1 fusions as a clinically actionable target, leading to new opportunities to increase patient referral due to a greater understanding of this ERBB[/HER]-targeted agents in NRG1 fusion-positive cancers. Researchers still do not fully understand many aspects of this targeting, raising the importance of foundational education to apprise clinicians of the latest mechanistic and preclinical data, so they become more comfortable to ask and detect and then refer.

The purpose of this program is to create awareness about the emergence of NRG1 fusions as a clinically actionable target, leading to new opportunities to increase patient referral due to a greater understanding of this ERBB[/HER]-targeted agents in NRG1 fusion-positive cancers. Researchers still do not fully understand many aspects of this targeting, raising the importance of foundational education to apprise clinicians of the latest mechanistic and preclinical data, so they become more comfortable to ask and detect and then refer.

The purpose of this program is to create awareness about the emergence of NRG1 fusions as a clinically actionable target, leading to new opportunities to increase patient referral due to a greater understanding of this ERBB[/HER]-targeted agents in NRG1 fusion-positive cancers. Researchers still do not fully understand many aspects of this targeting, raising the importance of foundational education to apprise clinicians of the latest mechanistic and preclinical data, so they become more comfortable to ask and detect and then refer.

The purpose of this program is to create awareness about the emergence of NRG1 fusions as a clinically actionable target, leading to new opportunities to increase patient referral due to a greater understanding of this ERBB[/HER]-targeted agents in NRG1 fusion-positive cancers. Researchers still do not fully understand many aspects of this targeting, raising the importance of foundational education to apprise clinicians of the latest mechanistic and preclinical data, so they become more comfortable to ask and detect and then refer.